XML 46 R29.htm IDEA: XBRL DOCUMENT
v3.22.1

Long-Term Investments (Tables) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2022 | Dec. 31, 2021
Long Term Investment [Abstract] |  |
Schedule of ownership percentages of investee |
|  | Ownership percentage |  |  |
|  | March 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2022 |  |  | 2021 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.17 | % |  |  | 0.17 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.70 | % |  |  | 0.70 | % |  | Cost Method
BioHopeKing Corporation |  |  | 5.90 | % |  |  | 5.90 | % |  | Cost Method
BioFirst Corporation |  |  | 15.99 | % |  |  | 15.99 | % |  | Equity Method
Rgene Corporation |  |  | 31.62 | % |  |  | 31.62 | % |  | Equity Method
|  | Ownership percentage |  |
|  | December 31, |  | December 31, |  | Accounting
Name of related party |  | 2021 |  | 2020 |  | treatments
Braingenesis Biotechnology Co., Ltd. |  | 0.17% |  | 0.17% |  | Cost Method
Genepharm Biotech Corporation |  | 0.70% |  | 0.70% |  | Cost Method
BioHopeKing Corporation |  | 5.90% |  | 5.90% |  | Cost Method
BioFirst Corporation |  | 15.99% |  | 15.99% |  | Equity Method
Rgene Corporation |  | 31.62% |  | 31.62% |  | Equity Method
Schedule of extent the investee relies |
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Collaborating with the Company to develop and commercialize drugs
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from the investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment |
|  | March 31, 2022 |  |  | December 31, 2021 |
|  | (Unaudited) |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,698 |  |  | $ | 7,941 |
Genepharm Biotech Corporation |  |  | 23,503 |  |  |  | 24,244 |
BioHopeKing Corporation |  |  | 873,053 |  |  |  | 900,570 |
Sub total |  |  | 904,254 |  |  |  | 932,755 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | - |  |  |  | - |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 904,254 |  |  | $ | 932,755 |
|  | December 31, 2021 |  |  | December 31, 2020 |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,941 |  |  | $ | 7,853 |
Genepharm Biotech Corporation |  |  | 24,244 |  |  |  | 23,974 |
BioHopeKing Corporation |  |  | 900,570 |  |  |  | 890,564 |
Sub total |  |  | 932,755 |  |  |  | 922,391 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | - |  |  |  | 268,336 |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 932,755 |  |  | $ | 1,190,727 |
Schedule of balance sheets |
|  | March 31, 2022 |  |  | December 31, 2021 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 2,147,097 |  |  | $ | 2,205,669 |
Non-current Assets |  |  | 812,865 |  |  |  | 959,454 |
Current Liabilities |  |  | 3,237,623 |  |  |  | 2,909,703 |
Non-current Liabilities |  |  | 17,741 |  |  |  | 32,522 |
Stockholders’ Equity |  |  | (295,402 | ) |  |  | 222,898 |
|  | March 31, 2022 |  |  | December 31, 2021 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 221,169 |  |  | $ | 73,452 |
Noncurrent Assets |  |  | 355,420 |  |  |  | 374,423 |
Current Liabilities |  |  | 2,164,077 |  |  |  | 1,934,786 |
Noncurrent Liabilities |  |  | - |  |  |  | - |
Shareholders’ Deficit |  |  | (1,587,488 | ) |  |  | (1,486,911 | )
|  | December 31, 2021 |  |  | December 31, 2020 |
Current Assets |  | $ | 2,205,669 |  |  | $ | 1,299,822 |
Noncurrent Assets |  |  | 959,454 |  |  |  | 2,540,041 |
Current Liabilities |  |  | 2,909,703 |  |  |  | 1,986,340 |
Noncurrent Liabilities |  |  | 32,522 |  |  |  | 73,197 |
Stockholders’ Equity |  |  | 222,898 |  |  |  | 1,780,326 |
|  | December 31, 2021 |  |  | December 31, 2020 |
Current Assets |  | $ | 73,452 |  |  | $ | 123,958 |
Noncurrent Assets |  |  | 374,423 |  |  |  | 412,342 |
Current Liabilities |  |  | 1,934,786 |  |  |  | 1,392,756 |
Noncurrent Liabilities |  |  | - |  |  |  | 38,953 |
Shareholders’ Deficit |  |  | (1,486,911 | ) |  |  | (895,409 | )
Schedule of statements of operation |
|  | Three Months Ended March 31, |
|  | 2022 |  |  | 2021 |
|  | (Unaudited) |
Net sales |  | $ | 8,808 |  |  | $ | 12,339 |
Gross profit |  |  | 6,133 |  |  |  | 7,080 |
Net loss |  |  | (498,940 | ) |  |  | (220,855 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  | (47,791 | )
|  | Three Months Ended March 31, |
|  | 2022 |  |  | 2021 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (149,480 | ) |  |  | (95,395 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Net sales |  | $ | 26,693 |  |  | $ | 257,235 |
Gross profit |  |  | 8,348 |  |  |  | 10,121 |
Net loss |  |  | (2,276,892 | ) |  |  | (5,401,074 | )
Share of losses from investments accounted for using the equity method |  |  | (269,844 | ) |  |  | (1,168,733 | )
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Net sales |  | $ | - |  |  | $ | 16,595 |
Gross Profit |  |  | - |  |  |  | (335,735 | )
Net loss |  |  | (576,514 | ) |  |  | (641,636 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
Schedule of equity investments |
|  | Three Months Ended March 31, |
|  | 2022 |  |  | 2021 |
|  | (Unaudited) |
Share of equity method investee losses |  | $ | - |  |  | $ | (47,791 | )
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Share of equity method investee losses |  | $ | (269,844 | ) |  | $ | (1,168,733 | )

X
- References No definition available. + Details
Name: | abvc_LongTermInvestmentAbstract
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of extent the investee relies. + References No definition available. + Details
Name: | abvc_ScheduleOfExtentInvesteeReliesTableTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_ScheduleOfLongTermInvestmentTableTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 12 -Paragraph (a) -Subsection 04 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690 + Details
Name: | pf0_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | pf0_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 12 -Paragraph (a) -Subsection 04 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690 + Details
Name: | pf0_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | pf0_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration